Licensing status

Publication and contact information

Ophthalmic disease

Age-related macular degeneration (AMD)


Mouse studies suggest recombinant IL-18 could help treat AMD. Knockout of Il-18 in mice results in AMD-like pathological neovascularization in the eye. In a mouse model of laser-induced choroidal neovascularization (CNV), intravitreal injection or systemic treatment with recombinant human IL-18 attenuated CNV neovascularization without affecting retinal pigment epithelial cell integrity. In the same mouse model, intravitreal injection of an anti-VEGF antibody plus subcutaneous injection of IL-18 increased CNV suppression compared with injection of the anti-VEGF antibody alone. Next steps include conducting further safety studies before designing a clinical study to treat AMD.

SciBX 7(18); doi:10.1038/scibx.2014.532
Published online May 8, 2014

Patent application filed covering use of IL-18 for CNV secondary to AMD; IP covered under an option agreement with GlaxoSmithKline plc

Doyle, S.L. et al. Sci. Trans. Med.; published online April 2, 2014;
Contact: Matthew Campbell, Smurfit Institute of Genetics at Trinity College Dublin,
Dublin, Ireland
Contact: Sarah L. Doyle, Trinity College Dublin, Dublin, Ireland